GSK
Biopharmaceuticals · United Kingdom
GSK discovers, makes and sells vaccines and specialty and general medicines for HIV, respiratory disease, cancer and infections, led by Shingrix, Trelegy and Dovato.
What makes it different
It delivers over a million vaccine doses every day.
1MVaccine doses a dayFY2025
Vaccines are more than a quarter of sales and run alongside specialty and general medicines.
How big it is
How big is GSK?
£32.7BTurnoverFY2025
66,841Employees2025
£7.5BR&D expenseFY2025
How it makes money FY2025
Specialty medicines lead; vaccines are over a quarter.
- Specialty Medicines41%£13.5B
- General Medicines31%£10.0B
- Vaccines28%£9.2B
How the business works
Prevent disease. Treat it. Refill the pipeline.
- 1Vaccines for every age
- 2Specialty and general medicines
- 3Pipeline from deals and R&D
HIV sales run through majority-owned ViiV Healthcare, and loss of dolutegravir exclusivity in 2028-2030 is the main pressure point.
Who owns it
- BlackRock, Inc.5.69%
- Dodge & Cox5.04%
CEO: Luke Miels
Who it competes with
Key moments
- 2-27Glaxo Wellcome and SmithKline Beecham merge
- 3-02Novartis transaction completes
- 2019Acquires Tesaro
- 7-31Consumer Healthcare joint venture with Pfizer
- 7-18Haleon demerged
Sources
Every number on this page comes from GSK's own reports.
Full profile
The rest of the story is in the app.
What GSK tracks28 metrics
R&D ratio
People reached with medicines and vaccines
Employees
Results, quarter by quarterwith a chart
Revenue
Profit
Margin
Where the money comes from4 regions
United States
International
Europe (excl. UK)
The full timeline19 moments
2024
2025
2026
GSK vs Pfizerside by side
Revenue
Profit
People
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
